Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Avidity Biosciences Inc (RNA)
NASDAQ:RNA
Holding RNA?
Track your performance easily
RNA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.79 - $56.00
Previous Close$36.85
Volume838.54K
Average Volume (3M)1.28M
Market Cap
$4.40B
Enterprise Value$2.82B
Total Cash (Recent Filing)$1.59B
Total Debt (Recent Filing)$7.60M
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Mar 04, 2025EPS Estimate
-$0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.90
Shares Outstanding119,309,317
10 Day Avg. Volume1,092,900
30 Day Avg. Volume1,279,230
Standard Deviation0.23
R-Squared0.03
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)2.87
Price to Sales (P/S)434.57
Price to Cash Flow (P/CF)-16.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue278.30
Enterprise Value/Gross Profit294.51
Enterprise Value/Ebitda-9.78
Forecast
1Y Price Target
$67.80Price Target Upside87.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Avidity Biosciences News
PremiumCompany Announcements
Avidity Biosciences Unveils Advances in Cardiology Research
PremiumCompany Announcements
Avidity Biosciences Reports Strong Q3 Progress and OutlookBulls Say, Bears Say
Bulls Say
Drug Development PipelineThe company announced two new lead candidates for cardiomyopathies using its innovative AOC technology, indicating advancement in its drug development pipeline.
Precision CardiologyRNA's recent expansion of their platform to include candidates in precision cardiology was discussed in an insightful investor and analyst webcast.
Technological AdvancementsNext-generation platform innovations could improve siRNA delivery 30-fold in skeletal muscle, suggesting potential for improved therapeutic durability and patient compliance.
Bears Say
Clinical TrialsAn instance of anaphylaxis and an infusion reaction led to two discontinuations in the study.
Financial PerformanceRNA reported a net loss of $80.4 million for the third quarter.
Regulatory ChallengesIn Sep 2022, del-desiran Ph1/2 MARINA was placed on partial clinical hold due to treatment-related serious adverse event of bilateral stroke in one patient in the 4mg/kg cohort.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
RNA FAQ
What was Avidity Biosciences Inc’s price range in the past 12 months?
Avidity Biosciences Inc lowest stock price was $6.79 and its highest was $56.00 in the past 12 months.
What is Avidity Biosciences Inc’s market cap?
Currently, no data Available
When is Avidity Biosciences Inc’s upcoming earnings report date?
Avidity Biosciences Inc’s upcoming earnings report date is Mar 04, 2025 which is in 76 days.
How were Avidity Biosciences Inc’s earnings last quarter?
Avidity Biosciences Inc released its earnings results on Nov 07, 2024. The company reported -$0.65 earnings per share for the quarter, beating the consensus estimate of -$0.711 by $0.061.
Is Avidity Biosciences Inc overvalued?
According to Wall Street analysts Avidity Biosciences Inc’s price is currently Undervalued.
Does Avidity Biosciences Inc pay dividends?
Avidity Biosciences Inc does not currently pay dividends.
What is Avidity Biosciences Inc’s EPS estimate?
Avidity Biosciences Inc’s EPS estimate is -$0.76.
How many shares outstanding does Avidity Biosciences Inc have?
Avidity Biosciences Inc has 119,309,320 shares outstanding.
What happened to Avidity Biosciences Inc’s price movement after its last earnings report?
Avidity Biosciences Inc reported an EPS of -$0.65 in its last earnings report, beating expectations of -$0.711. Following the earnings report the stock price went down -1.663%.
Which hedge fund is a major shareholder of Avidity Biosciences Inc?
Among the largest hedge funds holding Avidity Biosciences Inc’s share is RA Capital Management. It holds Avidity Biosciences Inc’s shares valued at 289M.
---
Avidity Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$67.80 (87.81% Upside)
$67.80 (87.81% Upside)
Blogger Sentiment
Bullish
RNA Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 5.3%
Last 30 Days ▼ 5.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
388.72%
12-Months-Change
Fundamentals
Return on Equity
-27.76%
Trailing 12-Months
Asset Growth
186.27%
Trailing 12-Months
Company Description
Avidity Biosciences Inc
Avidity Biosciences Inc is a bio-technology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product candidate AOC 1001, is designed to treat a rare monogenic muscle disease.
---
RNA Stock 12 Month Forecast
Average Price Target
$67.80
▲(87.81% Upside)
Technical Analysis
Scholar Rock Holding
―
Fulcrum Therapeutics
―
Seres Therapeutics
―
Bolt Biotherapeutics
―
Best Analysts Covering RNA
1 Year
1 Year Success Rate
11/20 ratings generated profit
1 Year Average Return
+142.29%
reiterated a buy rating 2 months ago
Copying Yanan Zhu's trades and holding each position for 1 Year would result in 55.00% of your transactions generating a profit, with an average return of +142.29% per trade.
---